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1 |  INTRODUCTION
The World Health Organization (WHO) released a semi-
nal report, titled Cancer Pain Relief and Palliative Care in 
Children, in which it recommended that palliative care (PC) 
for children with cancer ought to begin at diagnosis, irrespec-
tive of prognosis.1 Other international health organizations—
the American Academy of Pediatrics (AAP),2 Institute of 
Medicine (IOM),3 European Association for Palliative Care 
(EAPC),4 and the Royal College of Paediatrics and Child 
Health (RCPCH)5—have all since adopted a similar recom-
mendation.6 These calls for earlier PC are grounded in evi-
dence of an unmet need: the high illness burden and degree 
of suffering are well established among children with can-
cer.7 Additionally, numerous studies have demonstrated that 
the tight prognostic limits of hospice—a type of PC reserved 
for the end‐of‐life—are incompatible with the full spectrum 
of physical, psychological, social, and spiritual needs.8-10 PC 
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Abstract
Palliative care (PC) aims to improve quality of life for patients and their families. 
The World Health Organization and American Academy of Pediatrics recommend 
that PC starts at diagnosis for children with cancer. This systematic review describes 
studies that reported PC timing in the pediatric oncology population. The following 
databases were searched: PubMed, Web of Science, CINAHL, and PsycInfo data-
bases. Studies that reported time of PC initiation were independently screened and 
reviewed by 2 researchers. Studies describing pilot initiatives, published prior to 
1998, not written in English, or providing no empirical time information on PC were 
excluded. Extracted data included sample characteristics and timing of PC discus-
sion and initiation. Of 1120 identified citations, 16 articles met the inclusion criteria 
and comprised the study cohort. Overall, 54.5% of pediatric oncology patients re-
ceived any palliative service prior to death. Data revealed PC discussion does not 
occur until late in the illness trajectory, and PC does not begin until close to time of 
death. Despite efforts to spur earlier initiation, many pediatric oncology patients do 
not receive any palliative care service, and those who do, predominantly receive it 
near the time of death. Delays occur both at first PC discussion and at PC initiation. 
Efforts for early PC integration must recognize the complex determinants of PC uti-
lization across the illness timeline.
K E Y W O R D S
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presents an effective solution as both children with cancer 
and their parents report significantly enhanced quality of life 
from PC involvement.11,12
With the improvements in medical therapy for pediatric 
oncology patients,13 children now survive for longer periods 
and require extended PC, making pediatric PC an increasingly 
important area of research.14,15 Recent studies have investi-
gated related ethical issues: how and when children should be 
involved in decision‐making16-19 and what disparities exist in 
PC access.20,21 Moreover, various studies have demonstrated 
PC for children with cancer is initiated late in the illness tra-
jectory,22-24 indicating a discrepancy between the normative 
recommendation for early integration and referral practices 
in pediatric oncology. Yet, no systematic review of the timing 
of PC initiation has been conducted to compile this growing 
body of literature.
Understanding the current state of PC timing is neces-
sary to inform efforts to expand PC access, increase the 
time that children benefit from PC, and better support pe-
diatric oncologists. As such, the purpose of this study was 
to systematically review literature describing the current 
timing practices of PC initiation in children with cancer. 
The two key events involved in the start of PC are the initial 
discussion with or without specialist consultation and the 
first instance of palliative service provided. If PC services 
started close to time of death, it is important to know if 
discussion occurred early and PC was deemed unnecessary, 
or if discussion also occurred late. Knowing the specific 
timing of these events will identify where in the care con-
tinuum barriers may lie. Thus, this review sought to answer 
a guiding questions: a) what time elapses between cancer 
diagnosis and PC discussion or consult; b) how long before 
death does PC discussion occur; c) what is the PC duration 
received before death, and d) what proportion of children 
receive PC.
2 |  METHODS
2.1 | Search methodology
This systematic review of literature on the timing of PC in 
pediatric oncology patients was performed in accordance with 
the Preferred Reporting Items for Systematic reviews and 
Meta‐Analysis (PRISMA) guidelines.25 Details of the sys-
tematic review protocol were registered on the PROSPERO 
International Prospective Register of Systematic Reviews 
(CRD42018108557). We searched PubMed, Web of Science, 
CINAHL, and PsycInfo for publications between 1 January 
1998 and 15 December 2017, examined the citations of in-
cluded articles for relevant additions, and solicited additional 
citations through discussion with topic experts. The year 1998 
was selected as the beginning date because the WHO de-
clared in this year that PC for children with cancer ought to 
begin at the time of diagnosis.1 The WHO declaration altered 
the paradigm of PC initiation, so practices prior to this date 
may not be comparable. We developed the following Boolean 
search phrase based on controlled vocabulary results from the 
Medical Subject Headings (MeSH) terms database: (Palliative 
OR Hospice OR End‐of‐Life) AND (Pediatric* OR Child* 
OR Adolescent* OR Teen*) AND (Cancer OR Oncology OR 
Tumor* OR Neoplas*) AND (Duration OR Start* OR Time 
death OR Timing death OR Begin OR Began OR Time re-
ferr* OR Timing referr*). The terms “hospice” and “end‐of‐
life” care were included in our search because researchers and 
healthcare staff commonly equate them with PC, but care was 
taken during screening and full‐text review to ensure the re-
ported data reflected the first iteration of PC. If the patients in 
the included study had not previously received PC, then that 
study was included because the described hospice or EOL care 
also represented the first time PC was provided. Our search 
yielded a total of 1220 titles and abstracts across all 4 databases 
(Table 1).
T A B L E  1  Search terms and search results on timing of pediatric palliative care
No. Search terms
Matches
PubMed CINAHL PsycINFO Web of Science
1 Palliative OR Hospice OR End of Life 121 923 41 833 28 926 136 362
2 Pediatric* OR Child* OR Adolescent* 
OR Teen*
2 104 073 414 163 631 834 1 529 829
3 Cancer OR Oncology OR Tumor* OR 
Neoplas*
2 585 401 268 727 76 791 2 552 665
4 Duration OR Start* OR Time death OR 
Timing death OR Begin OR Began OR 
Time referr* OR Timing referr*
822 311 103 473 185 668 1 810 823
5 1 And 2 And 3 And 4 704 55 81 380
Date of last search: 12th of August 2018
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2.2 | Exclusion criteria
We defined the following a priori exclusion criteria: a) re-
sults published after the 1998 starting date of our search, but 
based on data collected from patients prior to the 1998 WHO 
recommendation; b) neonates because the type, presentation, 
and management of neonate cancer differs from those of older 
children,19 c) case studies because these describe exceptional 
medical situations and would skew our review; d) pilot initia-
tives that report results of a focused trial to encourage earlier 
PC consultation without pretrial data; e) no empirical data 
relevant to at least one of the primary study questions; and f) 
articles written in a language other than English.
2.3 | Search results and data extraction
After duplicates were eliminated, two reviewers indepen-
dently screened the article titles and abstracts to identify rel-
evant articles. Of the 1137 unique citations identified, 1086 
were published in English; titles and abstracts were inde-
pendently screened by two authors, and 31 were selected for 
full‐text review, in addition to three articles identified from 
reference lists and expert consultation; 16 remained after full‐
text review and comprised the full study cohort (Figure 1).
The authors independently collected the necessary data 
using a purpose‐built Microsoft Excel extraction form: 
publication information, sample characteristics, and timing 
information from each of the articles. The two sets of ex-
tracted data were compared to validate the accuracy, and dis-
agreements were resolved by discussion and input of a third 
investigator.
2.4 | Analysis
All evaluated outcomes were included in meta‐analysis, in-
cluding three timeframes—time from diagnosis to first PC 
discussion, first discussion to death, and duration of PC 
provided—and proportion who received PC. A study was 
included in meta‐analysis if it reported mean with standard 
deviation or median with arithmetic range or interquartile 
range (IQR). For studies that only reported median and range, 
mean and standard deviation were calculated based on algo-
rithms presented by Hozo et al26 All time data were converted 
into days. Data integration was conducted using Hedges‐
Olkin weighting models for inverse variance.27 Random 
effect models were fitted by applying restricted maximum 
likelihood estimation, and Forest plots were constructed to 
visualize the results. All statistical procedures were executed 
with the metafor package in R‐statistical software.28 In cases 
of significant homogeneity and sufficient number of studies, 
Lipsey‐Wilson moderator analyses were performed to exam-
ine study (sample country [US/non‐US], publication year, 
terminology [PC‐only/non‐PC], and sample size) and clinical 
characteristics (principle diagnostic group [solid tumor/blood 
F I G U R E  1  PRISMA flowchart for 
inclusion of studies
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cancer]) as potential reasons for variability.29 A two‐sided 
P‐value ≤0.05 was considered significant for all analyses.
3 |  RESULTS
3.1 | Characteristics of studies describing 
PC initiation
Of the 1137 identified studies, 16 studies were included in 
our review. Mean sample size was 237.2 (standard devia-
tion = 294.5) patients and ranged from 17 to 1208 patients. 
Included data describes 3796 pediatric cancer patients, in-
cluding 1438 solid tumor and 1231 hematologic cancer pa-
tients. Fifteen articles performed a retrospective medical 
review of records to study the timing of PC initiation, and 
one study was a prospective observation across six institu-
tions (Table 2).30 Metrics in eight studies were representative 
of the pediatric oncology population, while the remaining 
examined subsets of this target population. Timing was a pri-
mary outcome in all 16 studies. While all studies used the 
phrase “palliative care,” it is important to note that six studies 
also used end‐of‐life (k = 4) or hospice (k = 2) care inter-
changeably with palliative care.
The 16 included studies were published between 2002 and 
2018. The median publication year was 2014, indicating that 
half of the studies were published in the last 4 years. Most 
studies (k = 9) reported timing of PC in North America, four 
in Europe, two in Asia, and one in Australia. However, there 
was little diversity in World Bank income classification: 15 
included from high‐income countries and one from an upper‐
middle‐income country.
3.2 | Time from diagnosis to PC discussion
Time from diagnosis to first PC discussion was reported in 
three studies, which included 485 pediatric oncology patients 
(Figure 2). In our random effects model, the weighted mean 
time to PC consult was 509.6 (standard error (SE) [95% con-
fidence interval (CI)]: 37.6 [435.9‐583.4]) days. PC discus-
sion did not occur at diagnosis as recommended by WHO 
and AAP guidelines (P < 0.0001). Test for heterogeneity 
suggested large variation in effect sizes within these stud-
ies (Q[2] = 11.7, P = 0.003), and Higgins I2 statistic dem-
onstrated 78.9% of variability is not attributable to sampling 
error. There was an insufficient number of studies for mod-
erator analysis.
3.3 | Time from PC discussion to death
Six studies, including 1571 patients, reported time from PC 
discussion to death with a weighted mean length of 85.6 (SE 
[95% CI]: 18.3 [49.8‐121.3]) days. Of note, this number is 
significantly smaller than the mean time from diagnosis to 
PC discussion, indicating that PC is discussed late in the 
illness timeline. An additional study reported median time 
was less than 37 days, but this study could not be included 
T A B L E  2  Study characteristics of publications included in review (n = 16)
Year Authors
Country of 
data collection Study method
Sample 
size
Represents  
population
Terms used for 
palliative care Study period
2002 De Graves et al32 Australia Retrospective review 17 Yes Palliative care 1999‐1999
2005 Bradshaw et al64 USA Retrospective review 145 Yes End of life 2000‐2001
2008 Menon et al65 Malaysia Retrospective review 247 No Palliative care 2001‐2007
2011 Feudtner et al30 USA & Canada Prospective data collection 102a Yes Palliative care 2008‐2008
2011 Tzuh‐Tang et al66 Taiwan Retrospective review 1208 No Hospice 2001‐2006
2012 Johnston et al23 Canada Retrospective review 273 Yes Palliative care 2006‐2009
2013 Jalmsell et al22 Sweden Retrospective review 95 Yes End of life 2007‐2009
2013 Thienprayoon et al67 USA Retrospective review 114 No Hospice 2006‐2010
2014 Vallero et al68 Italy Retrospective review 39 No Palliative therapy 2005‐2011
2015 Levine et al33 USA Retrospective review 277 No End of life 2001‐2005
2015 Vern‐Gross et al34 USA Retrospective review 134 Yes Palliative care 2001‐2005
2016 Levine et al69 USA Retrospective review 615 No Palliative care 2007‐2014
2016 Ullrich et al31 USA Retrospective review 147 No Palliative care 2004‐2012
2017 Ananth et al70 USA Retrospective review 125 Yes Palliative care 2010‐2014
2017 Hoell et al71 Germany Retrospective review 65 No End of life 2009‐2016
2018 Rost et al72 Switzerland Retrospective review 193 Yes Palliative care 2008‐2014
Representation of the target population is defined as whether the metrics reported by the study estimate the pediatric oncology population.
aNumber of cancer patients isolated from n = 515 cohort. 
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in our descriptive analysis because it did not report a meas-
ure of variation.30 In the two studies that reported both 
time from diagnosis to PC discussion and PC discussion to 
death, time from PC discussion to death was comparatively 
short, comprising 25.4% and 3.6% of the total illness dura-
tion.23,31 Heterogeneity was significant for this outcome 
(Q[5] = 1547.6, P < 0.0001), and Higgins I2 statistic was 
99.8%, suggesting much of the variability across studies was 
due to the heterogeneity. However, the role of individual 
moderators in this variation could not be investigated due to 
the small number of studies.
3.4 | Duration of PC
Time from formal PC initiation to death was reported in 
six studies, including 814 patients. One additional study re-
ported a mean PC duration of 69.4 days, but did not report a 
measure of variation and could not be integrated in our dura-
tion model.32 In the random effects model for PC duration, 
mean duration was 57.8 (SE [95% CI]: 19.9 [18.80‐96.8]) 
days. Two studies quantified both time from PC discussion 
to death and PC duration: Levine et al reported 144.2 and 
56.3 days, respectively, while Vern‐Gross and colleagues 
stated 64 and 31 days.33,34 Taken together, these findings re-
veal initial PC discussion does not often result in prompt PC 
initiation. Effect sizes varied across studies (Q[5] = 134.8, 
P < 0.0001), and 97.8% of variability came from a source 
other than sampling error. Again, moderator analyses could 
not be conducted due to the small number of studies.
3.5 | Proportion with PC
The weighted mean percentage of patients who received PC 
prior to death was 54.5% (SE [95% CI]: 8.2% [38.5%‐70.5%]) 
across 12 studies and 3467 patients. Higgins I2 statistic was 
99.2%; test of heterogeneity was significant (Q[11] = 2230, 
P < 0.0001), and moderator analysis was conducted to 
investigate the effects of methodological and sample 
characteristics.
In mixed‐effects models for moderator variables, in-
creasing sample size was associated with a decline in pro-
portion receiving PC (Q[1] = 6.1, P = 0.01). Mean PC 
F I G U R E  2  Timing and duration of 
palliative care provided to children with 
cancer
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proportions in US vs non‐US studies were 56.0 vs 53.0 
(Q[1] = 0.03, P = 0.86); PC proportion has not changed 
significantly over time (Q[1] = 1.4, P = 0.24). Studies ex-
clusively using the PC terminology reported a mean pro-
vision fraction of 54.2%, compared to 55.1% in studies 
that also used EOL or hospice terminology (Q[1] = 0.003, 
P = 0.96). In subgroup analysis by malignancy type, 
weighted proportion was 39.9% (95% CI: 12.0%‐67.9%) in 
studies with predominantly hematological malignancies, 
54.7% (29.7%‐79.6%) in those with mostly solid tumor 
patients, and 66.5% (27.1%‐100.0%) for studies in which 
principle cancer type could not be identified. Despite the 
variation, cancer type was not significant on moderator 
analysis (Q[2] = 1.3, P = 0.53) (Figure 3).
4 |  DISCUSSION
This systematic review summarizes the timing of PC ser-
vices for pediatric oncology patients reported in 16 publi-
cations published between 2002 and 2018. No systematic 
review has been conducted on the timing of PC initiation 
for children with cancer, and the present study is the first 
to compile the growing literature on pediatric oncology 
PC practices. Comparing PC provision within studies and 
across publications, it is apparent that PC integration was 
delayed at two time points: first PC discussion occurs late 
in the illness trajectory, and there is a delay between the 
initial conversation and start of PC. The growing number 
of publications and pilot initiatives demonstrate genuine 
energy to embed PC into conventional healthcare and im-
prove the timing of PC discussion.33,35-37 However, the re-
sults of this study suggest that PC integration at diagnosis 
remains an unmet objective.
Our finding that only 54.5% of pediatric oncology 
patients received any PC before death may suggest there 
are structural barriers that inhibit availability of PC. A 
multinational review of Children’s Oncology Group insti-
tutions, which serve more than 90% of pediatric oncology 
patients in the US, found only 60% of providers offer PC 
services.38 Potential reasons for the absence of PC services 
include lack of coordination between oncology providers 
and palliative programs outside the hospital, restrictive 
reimbursement models, and ambiguous roles of members 
in the care team.39 While previous studies established 
the deficiencies in hospital infrastructure and our results 
demonstrate the effects on timing of PC provision, the driv-
ers that cause hospitals to offer pediatric PC are not well 
understood. Further research is recommended to identify 
socioeconomic and geographic disparities associated with 
lower pediatric PC provision. Such research would identify 
areas where PC is underutilized in children with cancer and 
guide interventions to increase PC provision.
Another proposed explanation in literature for the lack of 
timely PC provision is the shortage of clinicians capable to 
deliver PC to children with cancer.40 In a survey of PC provid-
ers—physicians, nurses, and other staff members—one‐third 
of respondents cited insufficient training in PC as a barrier 
to earlier PC integration.41 The limited exposure to targeted 
PC education in residency and fellowship means hospitals do 
not have staff with the training to meet the palliative needs 
of pediatric oncology patients.42-44 Improvements have been 
made to increase training opportunities as the number of pe-
diatric PC fellowships in the US have doubled since 2013.45 
However, adequate workforce availability remains a priority 
to expand the number of institutions that can offer PC to chil-
dren with cancer.
Training in PC principles is not important solely for des-
ignated PC staff; communication by the primary oncologist 
has a critical role in initiating the first PC discussion with 
the patient and family. Physicians recognize the child’s poor 
prognosis, on average, almost twice as early as parents do and 
thus, are often given the task to communicate the bad news to 
parents, explain treatment complications, maintain hope, and 
F I G U R E  3  Proportion receiving 
palliative care in children with cancer
Random effects model
0.0 0.2 0.4 0.6 0.8 1.0
Rost et al. (2018)
Anath et al. (2017)
Ullrich et al. (2016)
Levine et al. (2016)
Vern−Gross et al. (2015)
Levine et al. (2015)
Vallero et al. (2014)
Thienprayoon et al. (2013)
Jalmsell et al (2013).
Johnston et al. (2012)
Tang et al. (2011)
Menon et al. (2008)
193
125
147
615
134
277
39
114
95
273
1208
247
0.8 [0.7, 0.8]
0.8 [0.8, 0.9]
0.3 [0.2, 0.3]
0.6 [0.5, 0.6]
0.5 [0.4, 0.5]
0.4 [0.4, 0.5]
0.8 [0.7, 0.9]
0.8 [0.8, 0.9]
0.9 [0.8, 0.9]
0.2 [0.1, 0.2]
0.1 [0.1, 0.1]
0.5 [0.4, 0.5]
0.5 [0.4, 0.7]
Authors (Year) k Proportion [95% CI]
Proportion that received PC
PC proportion
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calibrate parental expectations.46 Physicians, however, do not 
consistently articulate this prognosis effectively to the family 
of children with cancer: parents are more likely than their 
treating oncologist to indicate the primary goal is cure,47 and 
61% of parents were more optimistic about their child’s odds 
of a cure than the physician was.15 Physicians view broaching 
PC as a stressor and delay the conversation, focusing instead 
on treatment arrangements.48,49
Formal training is associated with feeling comfortable to 
manage end‐of‐life issues, but 75% of pediatric oncologists 
have not had any formal end‐of‐life training.50 This com-
munication deficit may cause parents to be overly optimis-
tic and encourage them to pursue aggressive treatment until 
the physician is certain of their child’s imminent death.47 
Communication skills trainings, supporting resources, and 
a team‐based approach have shown promise as a means to 
facilitate earlier advance care planning and PC referral.51,52
Multiple studies have cited conceptual confusion be-
tween PC and hospice or EOL care, as well as the stigma of 
hopelessness associated with PC, as significant obstacles to 
early PC discussions.6,53-56 The International Classification 
of Disease coding system considers hospice and end‐of‐life 
care as synonymous with palliative care, and US clinicians 
are instructed to bill these services identically.57 There are 
even definitional inconsistencies between and among PC 
guidelines of what palliative care constitutes.58 If parents 
equate PC with EOL support, then it is understandable they 
will oppose the suggestion of PC at diagnosis or soon after. 
Yet, the Patient Protection and Affordable Care Act Section 
2302 “Concurrent Care for Children” recognizes the differ-
ence between PC and EOL care and guarantees coverage 
under Medicaid or the Children’s Health Insurance Program 
for concurrent hospice and curative care for all children 
under age 21.59 Adoption of a new phrase without the same 
connotations of death may support physicians in patient dis-
cussions. While the use of new terminology in pediatric on-
cology has not been tested, a survey found that compared to 
“supportive care,” the phrase “palliative care” was associated 
with decreased hope and increased distress in adult oncol-
ogy patients and their families.60 Furthermore, in a survey of 
646 Canadian physicians, pediatric oncologists reported they 
would refer patients earlier if PC was renamed “supportive 
care.”61 Additional research is warranted to devise methods 
to encourage earlier PC in the pediatric setting.
In moderator analysis, larger studies reported lower rates 
of PC utilization, suggesting that small single‐institution stud-
ies may overestimate PC provision. Future research on the 
topic should consider sample size and setting when designing 
studies. Literature in which hospice or EOL terminology was 
used did not vary in results when compared to studies that 
only used PC terminology; this indicates that despite the con-
notational significance of terminology in the clinical setting, 
researchers frequently use these phrases interchangeably. We 
recommend that researchers use caution to avoid confusion 
in reporting results and communicating findings to clinicians.
Finally, US location, temporal trend, and cancer type were 
not moderators of PC utilization. However, there was nota-
ble difference in rates between blood cancer and solid tumor. 
Pediatric blood cancers tend to have higher survival rates 
than solid tumors,62 which raises concerns that hematological 
cancer patients may receive more aggressive curative therapy 
until close to time of death. The low number of studies may 
explain why cancer type was not a significant co‐variate in 
our moderator analysis, but additional research is warranted to 
further investigate a possible difference by malignancy type.
4.1 | Limitations
Our analyses coalesce data across multiple sites and countries, 
which increase our confidence that these findings reflect true 
practice. All included studies were retrospective medical re-
cords reviews or prospective collection, which enhances the 
comparability across studies and reduces the chance of meas-
urement error. Additionally, 12 of our 16 studies had sample 
sizes with k > 100. As such, we could calculate robust estima-
tions of true effects. There are also limitations to our study. 
Inherent to systematic reviews, all included data were already 
published and may be affected by publication bias. Second, 
studies primarily originated from research in well‐developed 
regions of the world. Research is needed outside of developed 
countries to better understand the state of PC access and avail-
ability for children with cancer worldwide.
Sample size may partially explain the variation in PC 
timing observed in our results. Yet, there are other potential 
moderators that were not reported and could not be tested. 
Culturally determined understandings of when a condition is 
considered terminal (eg prognosis smaller than 10% vs 5%) 
may affect timing in different settings. Other demographic 
(eg income, ethnicity), clinical (eg comorbid chronic con-
ditions), and methodological (eg different definitions of 
when PC began) characteristics may also provide valuable 
context for the observed results and thus, warrant further 
study. Aside from these limitations, this study is the first 
systematic review on the timing of PC and sets a foundation 
for efforts to improve quality of life for children with cancer.
5 |  CONCLUSION
Our results underscore that PC starts too late for children 
with cancer and are not in line with the recommended AAP, 
WHO, IOM, EAPC, and RCPCH guidelines.1,2,4,5 Palliative 
care discussion does not occur until far into the illness, and 
PC does not start until much later. Each case is unique and 
must be evaluated using the caring physician’s best medi-
cal judgment and with respect to the patient and family, but 
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holistically, there is much room for improvement regarding 
PC timing for this patient population. Effective, timely com-
munication maintains patient quality of life and dovetails the 
transition to palliative care, while poor communication may 
lead to poor treatment planning and psychological harms for 
the child and family.63 Reasons for delayed discussion and 
initiation include insufficient resources and infrastructure, 
lack of training, and negative connotations attached to PC.
Findings in the present study regarding timings of PC dis-
cussion and initiation suggest pronounced obstacles across 
the PC lifecycle. As such, initiatives focused on specific re-
ferral points likely will not succeed. Programs designed to 
target PC timing must be robust and coordinated across the 
PC lifecycle to achieve effective improvement. Palliative care 
is central in pediatric oncology, and continued advocacy is 
necessary to promote optimal care for this patient population.
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